185 related articles for article (PubMed ID: 37604811)
21. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of new prognostic signature based on ferroptosis-related genes in clear cell renal cell carcinoma.
Zheng B; Niu Z; Si S; Zhao G; Wang J; Yao Z; Cheng F; He W
Aging (Albany NY); 2021 Aug; 13(15):19789-19804. PubMed ID: 34370716
[TBL] [Abstract][Full Text] [Related]
23. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract][Full Text] [Related]
24. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract][Full Text] [Related]
25. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
26. SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
Wang J; Yin X; He W; Xue W; Zhang J; Huang Y
Acta Pharm Sin B; 2021 Feb; 11(2):406-419. PubMed ID: 33643820
[TBL] [Abstract][Full Text] [Related]
27. High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma.
Wang J; Wen J; Yi R; Liu F; Zhou J; Liu G; Li Q; Yang Z; Su X
J BUON; 2015; 20(5):1267-75. PubMed ID: 26537074
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma.
Santos VE; da Costa WH; Bezerra SM; da Cunha IW; Nobre JQC; Brazão ES; Meduna RR; Rocha MM; Fornazieri L; Zequi SC
Clin Genitourin Cancer; 2021 Aug; 19(4):339-345. PubMed ID: 33839039
[TBL] [Abstract][Full Text] [Related]
29. SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer.
Rao H; Liu C; Wang A; Ma C; Xu Y; Ye T; Su W; Zhou P; Gao WQ; Li L; Ding X
Nat Commun; 2023 Nov; 14(1):7572. PubMed ID: 37989747
[TBL] [Abstract][Full Text] [Related]
30. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
31. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
32. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
33. A novel ferroptosis-related gene signature associated with cell cycle for prognosis prediction in patients with clear cell renal cell carcinoma.
Chen S; Zhang E; Guo T; Shao J; Wang T; Zhang N; Wang X; Zheng J
BMC Cancer; 2022 Jan; 22(1):1. PubMed ID: 34979993
[TBL] [Abstract][Full Text] [Related]
34. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
[TBL] [Abstract][Full Text] [Related]
35. Ferroptosis-Related Long Noncoding RNA Signature Predicts Prognosis of Clear Cell Renal Carcinoma.
Liu JW; Supandi F; Dhillon SK
Folia Biol (Praha); 2022; 68(1):1-15. PubMed ID: 36201853
[TBL] [Abstract][Full Text] [Related]
36. Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Zhou Y; Zheng X; Xu B; Deng H; Chen L; Jiang J
Aging (Albany NY); 2020 Nov; 12(24):25189-25206. PubMed ID: 33223508
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma.
Ju L; Shi Y; Liu G
PeerJ; 2022; 10():e14506. PubMed ID: 36570012
[TBL] [Abstract][Full Text] [Related]
38. MITD1 Deficiency Suppresses Clear Cell Renal Cell Carcinoma Growth and Migration by Inducing Ferroptosis through the TAZ/SLC7A11 Pathway.
Zhang Y; Li Y; Qiu Q; Chen Z; Du Y; Liu X
Oxid Med Cell Longev; 2022; 2022():7560569. PubMed ID: 36046690
[TBL] [Abstract][Full Text] [Related]
39. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Tong P; Wang J; Castle EP; Stanton ML; Cheville JC; Jonasch E; Brugarolas J; Parker AS
Mod Pathol; 2016 Jan; 29(1):34-42. PubMed ID: 26516698
[TBL] [Abstract][Full Text] [Related]
40. CX3CL1 promotes cell sensitivity to ferroptosis and is associated with the tumor microenvironment in clear cell renal cell carcinoma.
Gong Q; Guo Z; Sun W; Du X; Jiang Y; Liu F
BMC Cancer; 2022 Nov; 22(1):1184. PubMed ID: 36397015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
